ANXA5

(redirected from Annexin A5)
Also found in: Wikipedia.

ANXA5

A gene on chromosome 4q27 that encodes annexin 5, a calcium-dependent phospholipid-binding protein that inhibits phospholipase A2 and protein kinase C kinase, has anticoagulant activity, and may have a role in cell signal transduction, inflammation, growth and differentiation.
References in periodicals archive ?
Stolk et al., "Past, present, and future of annexin A5: from protein discovery to clinical applications," Journal of Nuclear Medicine, vol.
Protein samples were separated by electrophoresis on 10% acrylamide gels and annexin A5 was detected by western blotting using an anti-ANXA5 antibody purchased from Santa Cruz antibodies.
Abbreviations ANXA5: Annexin A5 AVD: Apoptotic volume decrease [BK.sub.Ca][alpha]: Large conductance voltage-activated and calcium-sensitive potassium channel subunit HEK 293 cells: Human embryonic kidney cells HO-2: Heme oxygenase-2 TEA: Tetraethylammonium FCCP: Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone HEPES: N-2-Hydroxyethylpiperazine-N -2 ethanesulfonic acid [[[Ca.sup.2+]].sub.o]: Extracellular calcium concentration [[[Ca.sup.2+]].sub.i]: Intracellular calcium concentration EGTA: Ethylene-glycol-tetra-acetic acid CORM-2: Tricarbonyldichlororuthenium (II) dimer ([[Ru(C[O.sub.3])[Cl.sub.2]].sub.2].
Shibata et al., "Development and evaluation of a novel [sup.99m]Tc-labeled annexin A5 for early detection of response to chemotherapy," PLoS ONE, vol.
Devos et al., "Site-specific [sup.68]Ga-labeled Annexin A5 as a PET imaging agent for apoptosis," Nuclear Medicine and Biology, vol.
Athera Biotechnologies AB, has transferred the rights to the recombinant Annexin A5 to Medirista AB.
Recombinant Annexin A5 has been developed to preclinical stage by Athera as an anti-inflammatory therapy, primarily targeting prevention of complications following vascular surgery.
(4) These include APA interference with endogenous anticoagulant mechanisms (disruption of the annexin A5 anticoagulant shield, (5) inhibition of the protein C pathway, inhibition of antithrombin), binding and activation of platelets, interactions with endothelial cells inducing expression of adhesion molecules and tissue factor, and activation of the complement cascade.
Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome.
reported the functional interactions between BKCa [alpha]-subunit and Annexin A5 in cell apoptosis.